A novel role of complement in retinal degeneration

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7684-7692

  Yu, Minzhong ^a   Zou, Weilin ^a   Peachey, Neal S ^a,b,c   McIntyre, Thomas M ^a,c   Liu, Jinbo ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ARACHIDONIC ACID; CASPASE 3; COMPLEMENT; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A RECEPTOR; LINOLEIC ACID; LYSOPHOSPHATIDYLCHOLINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LOSS; COMPLEMENT SYSTEM; CONTROLLED STUDY; ELECTRORETINOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; HISTOLOGY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LIGHT EXPOSURE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINA DEGENERATION; RETINAL NERVE FIBER LAYER THICKNESS; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5; DISEASE MODELS, ANIMAL; DNA; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; MACULAR DEGENERATION; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINA;

EID: 84872187295     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10069     Document Type: Article

References (57)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.
2. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129:75-80.
3. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308:421-424.
4. Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet. 2009;46:300-307.
5. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102: 7227-7232.
6. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308: 419-421.
7. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
8. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458-462.
9. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553-561.
10. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128:349-358.
11. Khandhadia S, Cipriani V, Yates JR, Lotery AJ. Age-related macular degeneration and the complement system. Immuno-biology. 2012;217:127-146.
12. Zipfel PF, Lauer N, Skerka C. The role of complement in AMD. Adv Exp Med Biol. 2010;703:9-24.
13. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628-5636.
14. Tornetta MA, Foley JJ, Sarau HM, Ames RS. The mouse anaphylatoxin C3a receptor: molecular cloning, genomic organization, and functional expression. J Immunol. 1997; 158:5277-5282.
15. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991;349:614-617.
16. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant. 2010;15:486-491.
17. Liu J, Lin F, Strainic MG, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008; 180:5882-5889.
18. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimula-tory and survival signals to naive CD4{thorn} T cells. Immunity. 2008;28:425-435.
19. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-797.
20. Clark SJ, Perveen R, Hakobyan S, et al. Impaired binding of the age-related macular degeneration-associated complement Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem. 2010;285:30192-30202.
21. Hecker LA, Edwards AO. Genetic control of complement activation in humans and age related macular degeneration. Adv Exp Med Biol. 2010;703:49-62.
22. Karagianni N, Adamis AP. The case for complement and inflammation in AMD: open questions. Adv Exp Med Biol. 2010;703:1-7.
23. Mukherjee P, Pasinetti GM. The role of complement anaphyl-atoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol. 2000;105:124-130.
24. Rahpeymai Y, Hietala MA, Wilhelmsson U, et al. Complement: a novel factor in basal and ischemia-induced neurogenesis. Embo J. 2006;25:1364-1374.
25. Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells. 2009;27:2824-2832.
26. Markiewski MM, DeAngelis RA, Strey CW, et al. The regulation of liver cell survival by complement. J Immunol. 2009;182: 5412-5418.
27. Ingersoll SA, Martin CB, Barnum SR, Martin BK. CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model. Mol Immunol. 2010;48:219-230.
28. Langer HF, Chung KJ, Orlova VV, et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010;116: 4395-4403.
29. Mattapallil MJ, Wawrousek EF, Chan CC, et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/ 6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci. 2012; 53:2921-2927.
30. Greferath U, Grunert U, Wassle H. Rod bipolar cells in the mammalian retina show protein kinase C-like immunoreactiv-ity. J Comp Neurol. 1990;301:433-442.
31. Oguni M, Setogawa T, Shinohara H, Kato K. Calbindin-D 28 kD and parvalbumin in the horizontal cells of rat retina during development. Curr Eye Res. 1998;17:617-622.
32. Yu M, Sturgill-Short G, Ganapathy P, Tawfik A, Peachey NS, Smith SB. Age-related changes in visual function in cystathi-onine-beta-synthase mutant mice, a model of hyperhomocys-teinemia. Exp Eye Res. 2012;96:124-131.
33. Yu M, Peachey NS. Attenuation of oscillatory potentials in nob2 mice. Doc Ophthalmol. 2007;115:173-186.
34. Wu J, Peachey NS, Marmorstein AD. Light-evoked responses of the mouse retinal pigment epithelium. J Neurophysiol. 2004; 91:1134-1142.
35. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA. 1992;89:4544-4548.
36. Varela C, Igartua I, De la Rosa EJ, De la Villa P. Functional modifications in rod bipolar cells in a mouse model of retinitis pigmentosa. Vision Res. 2003;43:879-885.
37. Chen M, Muckersie E, Robertson M, Forrester JV, Xu H. Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina. Exp Eye Res. 2008;87:543-550.
38. Wenzel A, Grimm C, Samardzija M, Reme CE. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog Retin Eye Res. 2005;24:275-306.
39. da Silva Cunha KC, Fuly AL, de Araujo EG. A phospholipase A isolated from Lachesis muta snake venom increases the survival of retinal ganglion cells in vitro. Toxicon. 2011;57: 580-585.
40. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis. An approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682-14687.
41. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovasculariza-tion. Proc Natl Acad Sci USA. 2006;103:2328-2333.
42. Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol. 2012;40:18-26.
43. Yehoshua Z, Rosenfeld PJ, Albini TA. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin Ophthalmol. 2011;26:167-180.
44. Schmitz-Valckenberg S, Mossner A, Fleckenstein M, Wiede-mann P, Holz FG. Therapy approaches for geographic atrophy. Ophthalmologe. 2010;107:1016-1019.
45. Wang YP, Hui YN, Wang YS, Wang HY. Detection of C5a receptor expressions on human epiretinal membranes and cultured RPE cells by immunohistochemical staining. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003;19:221-222.
46. Vogt SD, Barnum SR, Curcio CA, Read RW. Distribution of complement anaphylatoxin receptors and membrane-bound regulators in normal human retina. Exp Eye Res. 2006;83: 834-840.
47. Heredia CD, Huguet J, Cols N, Engel P, Garcia-Calderon PA. Immune complexes in retinitis pigmentosa. Br J Ophthalmol. 1984;68:811-814.
48. Bamberg CE, Mackay CR, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal trans-duction. J Biol Chem. 2010;285:7633-7644.
49. Ward PA. Functions of C5a receptors. J Mol Med (Berl). 2009; 87:375-378.
50. O'Barr SA, Caguioa J, Gruol D, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol. 2001;166:4154-4162.
51. Kastl SP, Speidl WS, Kaun C, et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost. 2006;4:1790-1797.
52. Peng Q, Li K, Wang N, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol. 2009;183:6058-6068.
53. Thurman JM, Lenderink AM, Royer PA, et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol. 2007;178: 1819-1828.
54. Ahamed J, Venkatesha RT, Thangam EB, Ali H. C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J Immunol. 2004;172:6961-6968.
55. Martin CB, Ingersoll SA, Martin BK. Transcriptional control of the C3a receptor gene in glial cells: dependence upon AP-1 but not Ets. Mol Immunol. 2007;44:703-712.
56. Tanito M, Haniu H, Elliott MH, Singh AK, Matsumoto H, Anderson RE. Identification of 4-hydroxynonenal-modified retinal proteins induced by photooxidative stress prior to retinal degeneration. Free Radic Biol Med. 2006;41:1847-1859.
57. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008;14:194-198.